SEARCH

SEARCH BY CITATION

References

  • 1
    Furuta GT, Liacouras CA, Collins MH, Gupta SK, Justinich C, Putnam PE et al. Eosinophilic esophagitis in children and adults: a systematic review and consensus recommendations for diagnosis and treatment. Gastroenterology 2007;133:13421363.
  • 2
    Kapel RC, Miller JK, Torres C, Aksoy S, Lash R, Katzka DA. Eosinophilic esophagitis: a prevalent disease in the United States that affects all age groups. Gastroenterology 2008;134:13161321.
  • 3
    Vanderheyden AD, Petras RE, DeYoung BR, Mitros FA. Emerging eosinophilic (allergic) esophagitis: increased incidence or increased recognition? Arch Pathol Lab Med 2007;131:777779.
  • 4
    Aceves SS, Newbury RO, Dohil R, Schwimmer J, Bastian JF. Distinguishing eosinophilic esophagitis in pediatric patients: clinical, endoscopic, and histologic features of an emerging disorder. J Clin Gastroenterol 2007;41:252256.
  • 5
    Aceves SS, Newbury RO, Dohil R, Bastian JF, Broide DH. Esophageal remodeling in pediatric eosinophilic esophagitis. J Allergy Clin Immunol 2007;119:206212.
  • 6
    Mishra A, Wang M, Pemmaraju VR, Collins MH, Fulkerson PC, Abonia JP et al. Esophageal remodeling develops as a consequence of tissue specific IL-5 induced eosinophilia. Gastroenterology 2008;134:204214.
  • 7
    Straumann A, Spichtin HP, Grize L, Bucher KA, Beglinger C, Simon HU et al. Natural history of primary eosinophilic esophagitis: a follow-up of 30 adult patients for up to 11.5 years. Gastroenterology 2003;125:16601669.
  • 8
    Chehade M, Sampson HA, Morotti P, Magid MS. Esophageal subepithelial fibrosis in children with eosinophilic esophagitis. J Pediatr Gastroenterol Nutr 2007;45:319328.
  • 9
    Konikoff MR, Noel RJ, Blanchard C, Kirby C, Jameson SC, Buckmeier BK et al. A randomized, double-blind, placebo-controlled trial of fluticasone propionate for pediatric eosinophilic esophagitis. Gastroenterology 2006;131:13811391.
  • 10
    Aceves SS, Bastian JF, Newbury RO, Dohil R. Oral viscous budesonide: a potential new therapy for eosinophilic esophagitis in children. Am J Gastroenterol 2007;102:2271.
    Direct Link:
  • 11
    Schaefer ET, Fitzgerald JF, Molleston JP, Croffie JM, Pfefferkorn MD, Corkins MR et al. Comparison of oral prednisone and topical fluticasone in the treatment of eosinophilic esophagitis: a randomized trial in children. Clin Gastroenterol Hepatol 2008;6:165173.
  • 12
    Broide DH. Immunologic and inflammatory mechanisms that drive asthma progression to remodeling. J Allergy Clin Immunol 2008;121:560570.
  • 13
    Khalil MS, El Nahas AM, Blakemore AIF. Transforming growth factor-β1 SNPS: genetic and phenotypic correlations in progressive kidney insufficiency. Nephron Exp Nephrol 2005;101:e31e41.
  • 14
    Ravelli AM, Villanacci V, Ruzzenenti N, Grigolato P, Tobanelli P, Klersy C et al. Dilated intercellular spaces: a major morphological feature of esophagitis. J Pediatr Gastroenterol Nutr 2006;42:510515.
  • 15
    Silverman ES, Palmer LJ, Subramaniam V, Hallock A, Sheeba M, Vallone J et al. Transforming growth factor-β1 promoter polymorphism C-509T is associated with asthma. Am J Respir Crit Care Med 2004;169:214219.
  • 16
    Loke T, Mallett KH, Ratoff J, O’Connor BJ, Ying S, Meng Q et al. Systemic glucocorticoids reduce bronchial mucosal activation of activator protein 1 components in glucocorticoids-sensitive but not glucocorticoids-resistant asthmatic patients. J Allergy Clin Immunol 2006;118: 368375.
  • 17
    Tesuya U, Niimi A, Matsumoto H, Takemura M, Yamaguchi M, Matsuoaka H et al. TGFβ1 promoter polymorphism C-509T and pathophysiology of asthma. J Allergy Clin Immunol 2008;121:659664.